curevac nv - CVAC

CVAC

Close Chg Chg %
2.88 -0.13 -4.51%

Closed Market

2.75

-0.13 (4.51%)

Volume: 726.55K

Last Updated:

Nov 13, 2024, 4:00 PM EDT

Company Overview: curevac nv - CVAC

CVAC Key Data

Open

$2.80

Day Range

2.72 - 2.90

52 Week Range

2.22 - 6.28

Market Cap

$646.00M

Shares Outstanding

224.31M

Public Float

93.63M

Beta

2.61

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.34

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

446.22K

 

CVAC Performance

1 Week
 
-3.17%
 
1 Month
 
-5.50%
 
3 Months
 
-15.12%
 
1 Year
 
-50.81%
 
5 Years
 
N/A
 

CVAC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About curevac nv - CVAC

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

CVAC At a Glance

CureVac NV
Friedrich-Miescher-Strasse 15
Tübingen, Baden Wuerttemberg 72076
Phone 49-7071-9883-0 Revenue 58.12M
Industry Pharmaceuticals: Major Net Income -281,270,603.08
Sector Health Technology Employees 1,172
Fiscal Year-end 12 / 2024
View SEC Filings

CVAC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 15.997
Price to Book Ratio 1.651
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.929
Enterprise Value to Sales 9.142
Total Debt to Enterprise Value 0.087

CVAC Efficiency

Revenue/Employee 49,589.26
Income Per Employee -239,991.982
Receivables Turnover 1.466
Total Asset Turnover 0.065

CVAC Liquidity

Current Ratio 2.567
Quick Ratio 2.434
Cash Ratio 2.159

CVAC Profitability

Gross Margin -172.971
Operating Margin -524.577
Pretax Margin -483.591
Net Margin -483.96
Return on Assets -31.443
Return on Equity -49.339
Return on Total Capital -45.569
Return on Invested Capital -46.094

CVAC Capital Structure

Total Debt to Total Equity 8.091
Total Debt to Total Capital 7.485
Total Debt to Total Assets 5.306
Long-Term Debt to Equity 7.122
Long-Term Debt to Total Capital 6.589
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Curevac Nv - CVAC

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
55.71M 121.73M 70.86M 58.12M
Sales Growth
+185.81% +118.50% -41.79% -17.98%
Cost of Goods Sold (COGS) incl D&A
26.07M 297.19M 214.76M 158.65M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
16.65M 40.78M 28.00M 29.44M
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
-24.18% +1,039.97% -27.74% -26.13%
Gross Income
29.64M (175.46M) (143.90M) (100.53M)
Gross Income Growth
+299.06% -691.94% +17.99% +30.14%
Gross Profit Margin
+53.21% -144.14% -203.08% -172.97%
2020 2021 2022 2023 5-year trend
SG&A Expense
182.36M 1.07B 156.80M 204.35M
Research & Development
126.80M 959.35M 56.65M 115.88M
Other SG&A
55.56M 110.12M 100.16M 88.47M
SGA Growth
+77.58% +486.47% -85.34% +30.32%
Other Operating Expense
- - - (321.50K)
-
Unusual Expense
- - (641.09K) (929.76K)
-
EBIT after Unusual Expense
(152.71M) (1.24B) (300.06M) (303.95M)
Non Operating Income/Expense
29.89M 769.26M 42.10M 25.59M
Non-Operating Interest Income
2.36M 11.94M 4.21M 18.09M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
25.20M 12.22M 3.90M 2.70M
Interest Expense Growth
+1,441.94% -51.50% -68.12% -30.82%
Gross Interest Expense
25.20M 12.22M 3.90M 2.70M
Interest Capitalized
- - - -
-
Pretax Income
(148.02M) (487.56M) (261.86M) (281.06M)
Pretax Income Growth
-32.09% -229.38% +46.29% -7.33%
Pretax Margin
-265.70% -400.52% -369.56% -483.59%
Income Tax
(827.62K) (924.31K) (132.42K) 214.06K
Income Tax - Current - Domestic
(459.41K) (1.22M) (111.40K) 127.57K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(368.21K) 296.68K (21.02K) 86.49K
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(147.20M) (486.64M) (261.72M) (281.27M)
Minority Interest Expense
- - - -
-
Net Income
(147.20M) (486.64M) (261.72M) (281.27M)
Net Income Growth
-31.68% -230.61% +46.22% -7.47%
Net Margin Growth
-264.21% -399.76% -369.37% -483.96%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(147.20M) (486.64M) (261.72M) (281.27M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(147.20M) (486.64M) (261.72M) (281.27M)
EPS (Basic)
-1.1135 -2.6162 -1.3842 -1.2737
EPS (Basic) Growth
-86.20% -134.95% +47.09% +7.98%
Basic Shares Outstanding
132.20M 186.01M 189.07M 220.83M
EPS (Diluted)
-1.1135 -2.6162 -1.3842 -1.2737
EPS (Diluted) Growth
-86.20% -134.95% +47.09% +7.98%
Diluted Shares Outstanding
132.20M 186.01M 189.07M 220.83M
EBITDA
(136.06M) (1.20B) (272.70M) (275.44M)
EBITDA Growth
-21.23% -784.77% +77.35% -1.00%
EBITDA Margin
-244.22% -988.91% -384.87% -473.93%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 6.409
Number of Ratings 7 Current Quarters Estimate -0.245
FY Report Date 12 / 2024 Current Year's Estimate 0.60
Last Quarter’s Earnings 1.50 Median PE on CY Estimate N/A
Year Ago Earnings -1.195 Next Fiscal Year Estimate -0.421
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 N/A 3 6
Mean Estimate -0.25 N/A 0.60 -0.42
High Estimates -0.12 N/A 0.74 -0.11
Low Estimate -0.36 N/A 0.45 -0.66
Coefficient of Variance -40.06 N/A 24.21 -46.09

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 5
OVERWEIGHT 0 0 0
HOLD 3 3 3
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Curevac Nv in the News